Healthcare / BiotechnologyCanadian Sec
$0.09
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
1.4x
↓EV/EBITDA
N/A
•ROE
117.3%
↑Gross Margin
7.4%
↓Debt/Equity
0.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-63.0%
FCF CAGR
—
FCF margin
-709.4%
FCF / Net income
-0.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $369279.0 · net income $7.4M · FCF $-2.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $369279.00 | $369279.00 | $516831.00 | $6.4M | $7.3M |
| Net Income | $7.4M | $7.4M | $-4.8M | $5.1M | $-15.5M |
| EBITDA | $-4.4M | $-4.4M | $-6.0M | $6.9M | $-10.8M |
| EPS | 0.04 | 0.04 | -0.02 | 0.03 | -0.14 |
| Gross Margin | 7.4% | 7.4% | 26.6% | 72.4% | 72.1% |
| Operating Margin | -548.2% | -548.2% | -1320.3% | 15.5% | -114.5% |
| Net Margin | 2002.0% | 2002.0% | -922.5% | 79.4% | -211.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.29 | 0.29 | 2.99 | 1.20 | 3.84 |
| Current Ratio | 3.55 | 3.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.6M | $-2.6M | $2.1M | $1.7M | $2.7M |
| Returns | |||||
| ROE | 117.3% | 117.3% | -195.6% | 72.4% | -1143.0% |
| Valuation | |||||
| P/E | 1.42 | 1.42 | — | 4.00 | — |
| EV/EBITDA | — | — | — | 3.64 | — |
| P/B | 2.19 | 2.19 | 4.66 | 2.77 | 13.76 |
| Growth & Yield | |||||
| Revenue Growth | -28.5% | -28.5% | -91.9% | -12.3% | — |
| EPS Growth | 300.0% | 300.0% | -166.7% | 121.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-42.7%
EPS terminal req.
$0.01
Spread vs growth
342.7%
5Y implied EPS CAGR
-25.6%
EPS terminal req.
$0.01
Spread vs growth
325.6%
10Y implied EPS CAGR
-9.5%
EPS terminal req.
$0.01
Spread vs growth
309.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+41.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → 0.04
Residual
+41.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.